DUBLIN, Oct. 7, 2019 /PRNewswire/ -- Allergan plc
(NYSE: AGN), a leading global pharmaceutical company with a
more than 70-year heritage in eye care, today announced the
launch of three new over-the-counter (OTC)
REFRESH® RELIEVA™ products: REFRESH®
RELIEVA™, REFRESH® RELIEVA™ PF (preservative-free)
multidose, and REFRESH® RELIEVA™ FOR CONTACTS. This new
line of artificial tear formulations available in preserved,
preservative-free multidose, and a formula designed for contact
lens wearers, are specially formulated to relieve discomfort due to
eye dryness and to prevent further irritation.
REFRESH®, a doctor recommended brand of artificial
tears, continues to expand its portfolio by offering the only
family of products in the U.S. with
carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive
ingredient), glycerin, and HydroCell™ technology--Allergan's
proprietary sodium chloride (NaCl) free, glycerin-based solution
that enables hydration and maintains the volume of cells on the
ocular surface.
"We are pleased to expand our robust artificial tear portfolio
with REFRESH® RELIEVA™ products as we continue to
exemplify our commitment to innovation in eye care. This brand-new
line provides doctors and patients with three unique options to
treat patients' individual needs when it comes to dry, irritated
eyes and contact lens dryness," said Jag Dosanjh, Senior Vice
President, Allergan US Eye Care. "With REFRESH® RELIEVA™ FOR
CONTACTS, contact lens patients now have a new option. As the
number one selling brand in preservative-free artificial tears, it
was also important to us to introduce REFRESH® RELIEVA™ in a new,
convenient preservative-free bottle. Now patients can enjoy the
convenience of a multidose bottle with all the benefits of being
preservative-free."
Over 26 million people in the United States suffer
from symptoms of eye dryness, including irritation, burning,
dryness, and discomfort. Eye dryness can be caused by
advanced age, contact lens wear, certain medications, other medical
conditions, or environmental factors. Studies show
REFRESH® RELIEVA™ products improve the symptoms of
eye dryness in patients, with a low incidence of blur upon
installation.
- 70% of patients reported no blur when REFRESH®
RELIEVA™ and REFRESH® RELIEVA™ FOR CONTACTS was first
applied
"As eye dryness varies for each patient, I'm excited to have
three new artificial tear treatment options since we know that one
size doesn't fit all for patients," said Milton Hom, OD. "Different patients have
different needs and REFRESH® RELIEVA™ provides the diversity to
satisfy more patients. With a low-blur formula and
HydroCell™ technology REFRESH® RELIEVA™ will be my preferred
artificial tear."
About REFRESH® RELIEVA™
REFRESH® RELIEVA™
Lubricant Eye Drops are available in three formulations: preserved,
preservative-free and a formula for contact lens wearers. This trio
is the only family of products in the U.S. formulated with
carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive
ingredient), glycerin, and HydroCell™ technology. HydroCell™
technology is Allergan's proprietary NaCl-free, glycerin-based
solution that enables hydration and maintains the volume of cells
on the ocular surface. The REFRESH® RELIEVA™ family of
Lubricant Eye Drops expands the options within the trusted
REFRESH® line of artificial tears.
Learn more about REFRESH® RELIEVA™
at www.refreshbrand.com
About Allergan Eye Care
As a leader in eye
care, Allergan has discovered, developed, and delivered
some of the most innovative products in the industry for more than
70 years. Allergan has launched over 125 eye care
products and invested billions of dollars in new treatments for the
most prevalent eye conditions including glaucoma, ocular surface
disease, and retinal diseases such as diabetic macular edema and
retinal vein occlusion. Our eye care pipeline includes 13
additional agents for multiple ocular conditions.
Our commitment to the well-being of patients is also reflected
in philanthropy. Allergan and The Allergan
Foundation support more than 150 organizations around the
world working to improve lives and communities. We remain
steadfast in helping eye care providers deliver the best in patient
care through innovative products and outreach programs.
About Allergan plc
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland, is a global pharmaceutical leader
focused on developing, manufacturing and commercializing branded
pharmaceutical, device, biologic, surgical and regenerative
medicine products for patients around the
world. Allergan markets a portfolio of leading brands and
best-in-class products primarily focused on four key therapeutic
areas including medical aesthetics, eye care, central nervous
system and gastroenterology. As part of its approach to delivering
innovation for better patient care, Allergan has built
one of the broadest pharmaceutical and device research and
development pipelines in the industry.
With colleagues and commercial operations located in
approximately 100 countries, Allergan is committed to
working with physicians, healthcare providers and patients to
deliver innovative and meaningful treatments that help people
around the world live longer, healthier lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained
in this press release that refer to future events or other
non-historical facts are forward-looking statements that reflect
Allergan's current perspective on existing trends and information
as of the date of this release. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; risks associated with
divestitures, acquisitions, mergers and joint ventures; risks
related to impairments; uncertainty associated with financial
projections, projected cost reductions, projected debt reduction,
projected synergies, restructurings, increased costs, and adverse
tax consequences; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2018
and Allergan's Quarterly Report on Form 10-Q for the period ended
June 30, 2019. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements.
CONTACTS:
Allergan:
Investors:
Manisha
Narasimhan, PhD
(862) 261-7162
Media:
Lisa Brown
(862) 261-7320
Lisa Kim
(714) 246-3843
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-expands-refresh-portfolio-with-new-refresh-relieva-lubricant-eye-drop-product-line-300931148.html
SOURCE Allergan plc